3 August 2016

Holding(s) in Company

RNS Number : 1047G
Verona Pharma PLC
03 August 2016
 

 

 

 

i

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

  

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

 

 

Verona Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Other (please specify):

 

 

3. Full name of person(s) subject to the notification obligation: iii

 

 

 

Vivo Ventures VII, LLC

 

 

4. Full name of shareholder(s)

(if different from 3.):iv

 

 

Vivo Ventures fund VII, LP

Vivo Ventures VII Affiliates Fund, LP

5. Date of the transaction and date on which the threshold is crossed or

reached: v

 

July 29, 2016

 

6. Date on which issuer notified:

 

July 29, 2016

7. Threshold(s) that is/are crossed or reached: vi, vii

 

6.5% to 9.84% Change at Combined Interest Level

       

 

  8. Notified details:                                                                                                                                            

A: Voting rights attached to shares viii, ix

Class/type of shares

 

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of

Shares

Number of

Voting Rights

Number of shares

Number of voting rights

% of  voting rights x

 

Direct

Direct

xi

 

Indirect xii

 

Direct

 

Indirect

 

 

 

GB00B06GSH43

 

 

65,600,000

 

 

65,600,000

 

 

252,393,874

 

 

252,393,874

 

 

9.84%

 

 

B: Qualifying Financial Instruments

 

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be

acquired if the instrument is

exercised/ converted.

% of voting rights

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

xv, xvi

 

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion

period xviii

Number of voting rights instrument refers to

% of voting rights xix,

xx

 

Nominal

 

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

252,393,874

 

9.84%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

 

Vivo Ventures VII, LLC is the general partner of both Vivo Ventures Fund VII, LP (VV Fund VII) and Vivo Ventures VII Affiliates Fund, LP. (Affiliates Fund VII). Accordingly, Vivo Ventures VII, LLC may be deemed to have indirect beneficial ownership of shares of the Issuer directly owned by VV Fund VII and Affiliates Fund VII. As of the date of this filing, VV Fund VII and Affiliates Fund VII beneficially own 247,010,316 and 5,383,558 shares of Common Stock respectively.

 

 

 

 

 

 

  Proxy Voting:                                                                                                                                                    

 

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

 

 

 

13. Additional information:

 

14. Contact name:

Vivo Capital, LLC Attn: Cinthia Sheu

 

15. Contact telephone number:

 

+1-650-688-0818

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGURPRUPQUMW

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us